Literature DB >> 21943931

Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy.

Neal K Lakdawala1, Jens Jakob Thune, Barry J Maron, Allison L Cirino, Ole Havndrup, Henning Bundgaard, Michael Christiansen, Christian M Carlsen, Jean-François Dorval, Raymond Y Kwong, Steven D Colan, Lars V Køber, Carolyn Y Ho.   

Abstract

In hypertrophic cardiomyopathy (HC), electrocardiographic (ECG) changes have been postulated to be an early marker of disease, detectable in sarcomere mutation carriers when left ventricular (LV) wall thickness is still normal. However, the ECG features of mutation carriers have not been fully characterized. Therefore, we systematically analyzed ECGs in a genotyped HC population to characterize ECG findings in mutation carriers (G+) with and without echocardiographic LV hypertrophy (LVH), and to evaluate the accuracy of ECG findings to differentiate at-risk mutation carriers from genetically unaffected relatives during family screening. The ECG and echocardiographic findings were analyzed from 213 genotyped subjects (76 G+/LVH-, 57 G+/LVH+ overt HC, 80 genetically unaffected controls). Cardiac magnetic resonance imaging was available on a subset. Q waves and repolarization abnormalities (QST) were highly specific (98% specificity) markers for LVH- mutation carriers, present in 25% of G+/LVH- subjects, and 3% of controls (p <0.001). QST ECG abnormalities remained independently predictive of carrying a sarcomere mutation after adjusting for age and impaired relaxation, another distinguishing feature of G+/LVH- subjects (odds ratio 8.4, p = 0.007). Myocardial scar or perfusion abnormalities were not detected on cardiac magnetic resonance imaging in G+/LVH- subjects, irrespective of the ECG features. In overt HC, 75% had Q waves and/or repolarization changes, but <25% demonstrated common isolated voltage criteria for LVH. In conclusion, Q waves and repolarization abnormalities are the most discriminating ECG features of sarcomere mutation carriers with and without LVH. However, owing to the limited sensitivity of ECG and echocardiographic screening, genetic testing is required to definitively identify at-risk family members.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21943931      PMCID: PMC3215918          DOI: 10.1016/j.amjcard.2011.07.019

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy.

Authors:  S F Nagueh; L L Bachinski; D Meyer; R Hill; W A Zoghbi; J W Tam; M A Quiñones; R Roberts; A J Marian
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

2.  Usefulness of the pediatric electrocardiogram in detecting left ventricular hypertrophy: results from the Prospective Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) multicenter study.

Authors:  Shannon M Rivenes; Steven D Colan; Kirk A Easley; Samuel Kaplan; Kathy J Jenkins; Mohammed N Khan; Wyman W Lai; Steven E Lipshultz; Douglas S Moodie; Thomas J Starc; George Sopko; Weihong Zhang; J Timothy Bricker
Journal:  Am Heart J       Date:  2003-04       Impact factor: 4.749

3.  A point-score system for the ECG diagnosis of left ventricular hypertrophy.

Authors:  D W Romhilt; E H Estes
Journal:  Am Heart J       Date:  1968-06       Impact factor: 4.749

4.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho; Begoña López; Otavio R Coelho-Filho; Neal K Lakdawala; Allison L Cirino; Petr Jarolim; Raymond Kwong; Arantxa González; Steven D Colan; J G Seidman; Javier Díez; Christine E Seidman
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

5.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function.

Authors:  R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

6.  Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.

Authors:  Pascale Richard; Philippe Charron; Lucie Carrier; Céline Ledeuil; Theary Cheav; Claire Pichereau; Abdelaziz Benaiche; Richard Isnard; Olivier Dubourg; Marc Burban; Jean-Pierre Gueffet; Alain Millaire; Michel Desnos; Ketty Schwartz; Bernard Hainque; Michel Komajda
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

7.  Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations.

Authors:  B J Maron; H Niimura; S A Casey; M K Soper; G B Wright; J G Seidman; C E Seidman
Journal:  J Am Coll Cardiol       Date:  2001-08       Impact factor: 24.094

8.  Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho; Nancy K Sweitzer; Barbara McDonough; Barry J Maron; Susan A Casey; J G Seidman; Christine E Seidman; Scott D Solomon
Journal:  Circulation       Date:  2002-06-25       Impact factor: 29.690

9.  Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations.

Authors:  Ole Havndrup; Henning Bundgaard; Paal Skytt Andersen; Lars Allan Larsen; Jens Vuust; Keld Kjeldsen; Michael Christiansen
Journal:  Cardiovasc Res       Date:  2003-02       Impact factor: 10.787

10.  Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; E Ciró; P Spirito
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

View more
  21 in total

1.  Electrocardiogram interpretation in the athlete.

Authors:  E S Williams; D S Owens; J A Drezner; J M Prutkin
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-06

2.  Electrocardiographic versus echocardiographic left ventricular hypertrophy and sudden cardiac arrest in the community.

Authors:  Kumar Narayanan; Kyndaron Reinier; Carmen Teodorescu; Audrey Uy-Evanado; Harpriya Chugh; Karen Gunson; Jonathan Jui; Sumeet S Chugh
Journal:  Heart Rhythm       Date:  2014-03-18       Impact factor: 6.343

Review 3.  Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives.

Authors:  Georgios K Efthimiadis; Efstathios D Pagourelias; Thomas Gossios; Thomas Zegkos
Journal:  World J Cardiol       Date:  2014-02-26

4.  The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study.

Authors:  Carolyn Y Ho; Sharlene M Day; Steven D Colan; Mark W Russell; Jeffrey A Towbin; Mark V Sherrid; Charles E Canter; John L Jefferies; Anne M Murphy; Allison L Cirino; Theodore P Abraham; Matthew Taylor; Luisa Mestroni; David A Bluemke; Petr Jarolim; Ling Shi; Lynn A Sleeper; Christine E Seidman; E John Orav
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

5.  Electrocardiographic changes announcing the rapid development of apical hypertrophic cardiomyopathy in an adult male.

Authors:  Alfonso Freites; Ester Canovas; J Rubio
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-09-18       Impact factor: 1.468

6.  Using genetic testing to guide therapeutic decisions in cardiomyopathy.

Authors:  Neal K Lakdawala
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08

7.  Integrating Genetics and Medicine: Disease-Modifying Treatment Strategies for Hypertrophic Cardiomyopathy.

Authors:  Carolyn Y Ho
Journal:  Prog Pediatr Cardiol       Date:  2016-03

8.  Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy.

Authors:  Anne Marie Valente; Neal K Lakdawala; Andrew J Powell; Sarah P Evans; Allison L Cirino; E John Orav; Calum A MacRae; Steven D Colan; Carolyn Y Ho
Journal:  Circ Cardiovasc Genet       Date:  2013-05-20

Review 9.  Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation?

Authors:  Corrado Poggesi; Carolyn Y Ho
Journal:  J Muscle Res Cell Motil       Date:  2014-02-04       Impact factor: 2.698

10.  Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing.

Authors:  Luis R Lopes; Anna Zekavati; Petros Syrris; Mike Hubank; Claudia Giambartolomei; Chrysoula Dalageorgou; Sharon Jenkins; William McKenna; Vincent Plagnol; Perry M Elliott
Journal:  J Med Genet       Date:  2013-02-08       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.